Items where authors include "Clézardin, P."

Article

Puppo, M., Croset, M., Ceresa, D. et al. (7 more authors) (2024) Protective effects of miR-24-2-5p in early stages of breast cancer bone metastasis. Breast Cancer Research, 26. 186. ISSN 1465-5411

Puppo, M. orcid.org/0000-0003-1409-9577, Valluru, M.K. orcid.org/0000-0001-9156-866X, Croset, M. et al. (9 more authors) (2023) MiR-662 is associated with metastatic relapse in early-stage breast cancer and promotes metastasis by stimulating cancer cell stemness. British Journal of Cancer, 129 (5). pp. 754-771. ISSN 0007-0920

Puppo, M. orcid.org/0000-0003-1409-9577, Jaafar, M. orcid.org/0000-0001-7708-3826, Diaz, J.-J. et al. (2 more authors) (2023) MiRNAs and snoRNAs in bone metastasis: functional roles and clinical potential. Cancers, 15 (1). 242. ISSN 2072-6694

Puppo, M. orcid.org/0000-0003-1409-9577, Valluru, M.K. orcid.org/0000-0001-9156-866X and Clézardin, P. (2021) MicroRNAs and their roles in breast cancer bone metastasis. Current Osteoporosis Reports, 19 (3). pp. 256-263. ISSN 1544-1873

Puppo, M., Taipaleenmäki, H., Hesse, E. et al. (1 more author) (2021) Non‐coding RNAs in bone remodelling and bone metastasis : mechanisms of action and translational relevance. British Journal of Pharmacology, 178 (9). pp. 1936-1954. ISSN 0007-1188

Bouchet, M., Lainé, A., Boyault, C. et al. (13 more authors) (2020) ERRα expression in bone metastases leads to an exacerbated anti-tumor immune response. Cancer Research, 80 (13). pp. 2914-2926. ISSN 0008-5472

Das, S., Clézardin, P., Kamel, S. et al. (2 more authors) (2020) The CaSR in pathogenesis of breast cancer : a new target for early stage bone metastases. Frontiers in Oncology, 10 (1). 69.

Dewulf, J., Vangestel, C., Verhoeven, Y. et al. (4 more authors) (2019) Bone metastases in the era of targeted treatments : insights from molecular biology. The Quarterly Journal of Nuclear Medicine and Molecular Imaging, 63 (2). pp. 98-111. ISSN 1824-4785

Peters, S., Clézardin, P., Márquez-Rodas, I. et al. (2 more authors) (2019) The RANK–RANKL axis : an opportunity for drug repurposing in cancer? Clinical and Translational Oncology, 21 (8). pp. 977-991. ISSN 1699-048X

Vargas, G., Bouchet, M., Bouazza, L. et al. (22 more authors) (2019) ERRα promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors. Oncogene, 38 (7). pp. 950-964. ISSN 0950-9232

Lelièvre, L., Clézardin, P., Magaud, L. et al. (7 more authors) (2018) Comparative study of neoadjuvant chemotherapy with and without Zometa for management of locally advanced breast cancer with serum VEGF as primary endpoint: The NEOZOL study. Clinical Breast Cancer, 18 (6). e1311-e1321. ISSN 1526-8209

Gineyts, E., Bonnet, N., Bertholon, C. et al. (17 more authors) (2018) The C-terminal intact forms of periostin (iPTN) are surrogate markers for osteolytic lesions in experimental breast cancer bone metastasis. Calcified Tissue International, 103 (5). pp. 567-580. ISSN 0171-967X

Croset, M., Pantano, F., Kan, C.W.S. et al. (10 more authors) (2018) miRNA-30 family members inhibit breast cancer invasion, osteomimicry, and bone destruction by directly targeting multiple bone metastasis–associated genes. Cancer Research, 78 (18). pp. 5259-5273. ISSN 0008-5472

Sousa, S. and Clézardin, P. (2018) Bone-targeted therapies in cancer-induced bone disease. Calcified Tissue International, 102 (2). pp. 227-250. ISSN 0171-967X

Boudot, C., Hénaut, L., Thiem, U. et al. (8 more authors) (2017) Overexpression of a functional calcium-sensing receptor dramatically increases osteolytic potential of MDA-MB-231 cells in a mouse model of bone metastasis through epiregulin-mediated osteoprotegerin downregulation. Oncotarget, 8 (34).

Reynaud, C., Ferreras, L., Di Mauro, P. et al. (9 more authors) (2017) Lysyl oxidase is a strong determinant of tumor cell colonization in bone. Cancer Research, 77 (2). pp. 268-278. ISSN 0008-5472

Fradet, A., Bouchet, M., Delliaux, C. et al. (17 more authors) (2016) Estrogen related receptor alpha in castration-resistant prostate cancer cells promotes tumor progression in bone. Oncotarget, 7 (47). pp. 77071-77086.

Kan, C., Vargas, G., Pape, F. et al. (1 more author) (2016) Cancer cell colonisation in the bone microenvironment. International Journal of Molecular Sciences, 17 (10). 1674.

Le Pape, F., Vargas, G. and Clézardin, P. (2016) The role of osteoclasts in breast cancer bone metastasis. Journal of Bone Oncology, 5 (3). pp. 93-95. ISSN 2212-1366

Tardoski, S., Ngo, J., Gineyts, E. et al. (3 more authors) (2015) Low-intensity continuous ultrasound triggers effective bisphosphonate anticancer activity in breast cancer. Scientific Reports, 5. 16354. ISSN 2045-2322

Sahay, D., Leblanc, R., Grunewald, T.G.P. et al. (4 more authors) (2015) The LPA1/ZEB1/miR-21-activation pathway regulates metastasis in basal breast cancer. Oncotarget, 6 (24). pp. 20604-20620.

David, M., Sahay, D., Mege, F. et al. (5 more authors) (2014) Identification of heparin-binding EGF-like growth factor (HB-EGF) as a biomarker for lysophosphatidic acid receptor type 1 (LPA1) activation in human breast and prostate cancers. PLoS One, 9 (5). e97771. ISSN 1932-6203

Fradet, A., Sorel, H., Depalle, B. et al. (8 more authors) (2013) A new murine model of osteoblastic/osteolytic lesions from human androgen-resistant prostate cancer. PLoS One, 8 (9). e75092. ISSN 1932-6203

David, M., Ribeiro, J., Descotes, F. et al. (5 more authors) (2012) Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis. International Journal of Oncology, 40 (4). pp. 1133-1141. ISSN 1019-6439

Clézardin, P. (2011) Therapeutic targets for bone metastases in breast cancer. Breast Cancer Research, 13 (2). 207. ISSN 1465-5411

David, M., Wannecq, E., Descotes, F. et al. (12 more authors) (2010) Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts. PLoS One, 5 (3). e9741. ISSN 1932-6203